J&J Bounces Back In Q3, Led By Interventional Devices
Executive Summary
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.
You may also be interested in...
J&J Finishes Tough Year With Optimism For 2021
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
Boston Scientific Exceeds Wall Street’s Expectations In Q3
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.